^
CANCER:

Hepatocellular Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Hepatocellular Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
cabozantinib tablet
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
AFP elevation
Hepatocellular Cancer
ramucirumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
regorafenib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
lenvatinib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
sorafenib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
nivolumab + ipilimumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
tislelizumab
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
nivolumab
Sensitive
:
A2
NTRK3 fusion
Hepatocellular Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Hepatocellular Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Hepatocellular Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Hepatocellular Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Hepatocellular Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Hepatocellular Cancer
entrectinib
Sensitive
:
A2
No biomarker
Hepatocellular Cancer
sirolimus
Sensitive
:
A2
MSI-H/dMMR
Hepatocellular Cancer
dostarlimab
Sensitive
:
A2
No biomarker
Hepatocellular Cancer
durvalumab
Sensitive
:
A2
AFP elevation
Hepatocellular Cancer
regorafenib
Sensitive
:
B
FGF21-H
Hepatocellular Cancer
lenvatinib
Sensitive
:
B
No biomarker
Hepatocellular Cancer
SRF388
Sensitive
:
B
HGF-H + VEGFA-H
Hepatocellular Cancer
erlotinib + sorafenib
Resistant
:
B
VEGFA-H
Hepatocellular Cancer
lenvatinib
Resistant
:
B
HGF elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant
:
B
CXCL8 elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant
:
B
MET elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant
:
B
ANGPT2 elevation
Hepatocellular Cancer
cabozantinib tablet
Resistant
:
B
No biomarker
Hepatocellular Cancer
durvalumab + CP-675206
Sensitive
:
B
No biomarker
Hepatocellular Cancer
atezolizumab + cabozantinib tablet
Sensitive
:
B
FGFR2 fusion
Hepatocellular Cancer
infigratinib
Sensitive
:
C1